Shanghai United Imaging Healthcare Co., Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

The analysts might have been a bit too bullish on Shanghai United Imaging Healthcare Co., Ltd. (SHSE:688271), given that the company fell short of expectations when it released its yearly results last week. Results showed a clear earnings miss, with CN¥10b revenue coming in 6.6% lower than what the analystsexpected. Statutory earnings per share (EPS) of CN¥1.54 missed the mark badly, arriving some 26% below what was expected. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

Check out our latest analysis for Shanghai United Imaging Healthcare

Following the latest results, Shanghai United Imaging Healthcare's 18 analysts are now forecasting revenues of CN¥13.1b in 2025. This would be a substantial 27% improvement in revenue compared to the last 12 months. Per-share earnings are expected to soar 42% to CN¥2.18. In the lead-up to this report, the analysts had been modelling revenues of CN¥14.2b and earnings per share (EPS) of CN¥2.83 in 2025. The analysts seem less optimistic after the recent results, reducing their revenue forecasts and making a large cut to earnings per share numbers.

Despite the cuts to forecast earnings, there was no real change to the CN¥148 price target, showing that the analysts don't think the changes have a meaningful impact on its intrinsic value. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic Shanghai United Imaging Healthcare analyst has a price target of CN¥169 per share, while the most pessimistic values it at CN¥124. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. The analysts are definitely expecting Shanghai United Imaging Healthcare's growth to accelerate, with the forecast 27% annualised growth to the end of 2025 ranking favourably alongside historical growth of 18% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 18% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Shanghai United Imaging Healthcare to grow faster than the wider industry.

The Bottom Line

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Shanghai United Imaging Healthcare. They also downgraded Shanghai United Imaging Healthcare's revenue estimates, but industry data suggests that it is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Shanghai United Imaging Healthcare going out to 2027, and you can see them free on our platform here..

We also provide an overview of the Shanghai United Imaging Healthcare Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.